| 臺大學術典藏 |
2021-02-04T02:39:48Z |
Clinical factors associated with prognosis in low-grade serous ovarian carcinoma: experiences at two large academic institutions in Korea and Taiwan
|
Kang J.-H.;Lai Y.-L.;Cheng W.-F.;Kim H.-S.;Kuo K.-T.;Yu-Li Chen;Lee Y.-Y.; Kang J.-H.; Lai Y.-L.; Cheng W.-F.; Kim H.-S.; Kuo K.-T.; YU-LI CHEN; Lee Y.-Y. |
| 臺大學術典藏 |
2021-02-04T02:30:24Z |
Novel design for a dynamic ankle foot orthosis with motion feedback used for training in patients with hemiplegic gait: A pilot study
|
Hsu, C.-C.;Huang, Y.-K.;Kang, J.-H.;Ko, Y.-F.;Liu, C.-W.;Jaw, F.-S.;Chen, S.-C.Fu-Shan Jaw; Hsu, C.-C.; Huang, Y.-K.; Kang, J.-H.; Ko, Y.-F.; Liu, C.-W.; Jaw, F.-S.; Chen, S.-C.; FU-SHAN JAW |
| 臺大學術典藏 |
2021-01-29T03:17:22Z |
Association of dysmenorrhea with interstitial cystitis/bladder pain syndrome: A case-control study
|
Chung S.-D.;Shih-Ping Liu;Lin H.-C.;Kang J.-H.; Chung S.-D.; SHIH-PING LIU; Lin H.-C.; Kang J.-H. |
| 臺大學術典藏 |
2021-01-29T03:17:21Z |
Herpes zoster is associated with prior statin use: A population-based case-control study
|
Chung S.-D.;Tsai M.-C.;Shih-Ping Liu;Lin H.-C.;Kang J.-H.; Chung S.-D.; Tsai M.-C.; SHIH-PING LIU; Lin H.-C.; Kang J.-H. |
| 國立成功大學 |
2021 |
System modeling and characterization of enhanced valveless micropumps
|
Lai, H.-Y.;Kang, J.-H. |
| 臺大學術典藏 |
2020-12-02T02:33:36Z |
Characterization of large structural genetic mosaicism in human autosomes
|
Machiela M.J.; Zhou W.; Sampson J.N.; Dean M.C.; Jacobs K.B.; Black A.; Brinton L.A.; Chang I.-S.; Chen C.; Chen C.; Chen K.; Cook L.S.; Crous Bou M.; De Vivo I.; Doherty J.; Friedenreich C.M.; Gaudet M.M.; Haiman C.A.; Hankinson S.E.; Hartge P.; Henderson B.E.; Hong Y.-C.; Hosgood H.D.; Hsiung C.A.; Hu W.; Hunter D.J.; Jessop L.; Kim H.N.; Kim Y.H.; Kim Y.T.; Klein R.; Kraft P.; Lan Q.; Lin D.; Liu J.; Le Marchand L.; Liang X.; Lissowska J.; Lu L.; Magliocco A.M.; Matsuo K.; Olson S.H.; Orlow I.; Park J.Y.; Pooler L.; Prescott J.; Rastogi R.; Risch H.A.; Schumacher F.; Seow A.; Setiawan V.W.; Shen H.; Sheng X.; Shin M.-H.; Shu X.-O.; Vanden Berg D.; Wang J.-C.; Wentzensen N.; Wong M.P.; Wu C.; Wu T.; Wu Y.-L.; Xia L.; Yang H.P.; Pan-Chyr Yang; Zheng W.; Zhou B.; Abnet C.C.; Albanes D.; Aldrich M.C.; Amos C.; Amundadottir L.T.; Berndt S.I.; Blot W.J.; Bock C.H.; Bracci P.M.; Burdett L.; Buring J.E.; Butler M.A.; Carre?N T.; Chatterjee N.; Chung C.C.; Cook M.B.; Cullen M.; Davis F.G.; Ding T.; Duell E.J.; Epstein C.G.; Fan J.-H.; Figueroa J.D.; Fraumeni J.F.; Jr.; Freedman N.D.; Fuchs C.S.; Gao Y.-T.; Gapstur S.M.; Pati?O-Garcia A.; Garcia-Closas M.; Gaziano J.M.; Giles G.G.; Gillanders E.M.; Giovannucci E.L.; Goldin L.; Goldstein A.M.; Greene M.H.; Hallmans G.; Harris C.C.; Henriksson R.; Holly E.A.; Hoover R.N.; Hu N.; Hutchinson A.; Jenab M.; Johansen C.; Khaw K.-T.; Koh W.-P.; Kolonel L.N.; Kooperberg C.; Krogh V.; Kurtz R.C.; Lacroix A.; Landgren A.; Landi M.T.; Li D.; Liao L.M.; Malats N.; Mcglynn K.A.; Mcneill L.H.; Mcwilliams R.R.; Melin B.S.; Mirabello L.; Peplonska B.; Peters U.; Petersen G.M.; Prokunina-Olsson L.; Purdue M.; Qiao Y.-L.; Rabe K.G.; Rajaraman P.; Real F.X.; Riboli E.; Rodr?Guez-Santiago B.; Rothman N.; Ruder A.M.; Savage S.A.; Schwartz A.G.; Schwartz K.L.; Sesso H.D.; Severi G.; Silverman D.T.; Spitz M.R.; Stevens V.L.; Stolzenberg-Solomon R.; Stram D.; Tang Z.-Z.; Taylor P.R.; Teras L.R.; Tobias G.S.; Viswanathan K.; Wacholder S.; Wang Z.; Weinstein S.J.; Wheeler W.; White E.; Wiencke J.K.; Wolpin B.M.; Wu X.; Wunder J.S.; Yu K.; Zanetti K.A.; Zeleniuch-Jacquotte A.; Ziegler R.G.; De Andrade M.; Barnes K.C.; Beaty T.H.; Bierut L.J.; Desch K.C.; Doheny K.F.; Feenstra B.; Ginsburg D.; Heit J.A.; Kang J.H.; Laurie C.A.; Li J.Z.; Lowe W.L.; Marazita M.L.; Melbye M.; Mirel D.B.; Murray J.C.; Nelson S.C.; Pasquale L.R.; Rice K.; Wiggs J.L.; Wise A.; Tucker M.; P?Rez-Jurado L.A.; Laurie C.C.; Caporaso N.E.; Yeager M.; Chanock S.J.; Machiela M.J.; PAN-CHYR YANG et al. |
| 臺大學術典藏 |
2020-12-02T02:33:19Z |
Randomized phase II trial of gefitinib with and without pemetrexed as first-line therapy in patients with advanced nonsquamous non-small-cell lung cancer with activating epidermal growth factor receptor mutations
|
Cheng Y.; Murakami H.; Pan-Chyr Yang; He J.; Nakagawa K.; Kang J.H.; Kim J.-H.; Wang X.; Enatsu S.; Puri T.; Orlando M.; Yang J.C.-H.; Cheng Y.; PAN-CHYR YANG et al. |
| 臺大學術典藏 |
2020-12-02T02:33:06Z |
A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous NSCLC With EGFR Mutation: Final Overall Survival and Biomarker Analysis
|
Yang J.C.-H.; PAN-CHYR YANG et al.; Yang J.C.-H.; Cheng Y.; Murakami H.; Pan-Chyr Yang; He J.; Nakagawa K.; Kang J.H.; Kim J.-H.; Hozak R.R.; Nguyen T.S.; Zhang W.L.; Enatsu S.; Puri T.; Orlando M. |
| 臺大學術典藏 |
2020-08-13T06:33:55Z |
Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer: A combined clinical-molecular pathological approach
|
Lu S.; Thongprasert S.; Salto-Tellez M.; Tsao M.-S.; JIN-YUAN SHIH; Chang G.-C.; Au J.S.-K.; Chou T.-Y.; Lee J.-S.; Shi Y.-K.; Radzi A.; Kang J.-H.; Kim S.-W.; Tan S.-Y.; Yang J.C.-H. |
| 臺大學術典藏 |
2020-08-13T06:33:40Z |
East Asian subgroup analysis of a randomized, double-blind, phase 3 study of docetaxel and ramucirumab versus docetaxel and placebo in the treatment of stage IV non-small cell lung cancer following disease progression after one prior platinum-based therapy (REVEL)
|
Orlando M.; Puri T.; Alexandris E.; Lee P.; Zimmermann A.H.; Cho E.K.; Kang J.-H.; JIN-YUAN SHIH; Kim J.-H.; Park K. |
